{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:59:40Z","timestamp":1774645180366,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prioritizing genes for translation to therapeutics for common diseases has been challenging. Here, we propose an approach to identify drug targets with high probability of success by focusing on genes with both gain of function (GoF) and loss of function (LoF) mutations associated with opposing effects on phenotype (Bidirectional Effect Selected Targets, BEST). We find 98 BEST genes for a variety of indications. Drugs targeting those genes are 3.8-fold more likely to be approved than non-BEST genes. We focus on five genes (<jats:italic>IGF1R, NPPC, NPR2, FGFR3<\/jats:italic>, and <jats:italic>SHOX<\/jats:italic>) with evidence for bidirectional effects on stature. Rare protein-altering variants in those genes result in significantly increased risk for idiopathic short stature (ISS) (OR\u2009=\u20092.75, <jats:italic>p<\/jats:italic>\u2009=\u20093.99 \u00d7 10<jats:sup>\u22128<\/jats:sup>). Finally, using functional experiments, we demonstrate that adding an exogenous CNP analog (encoded by <jats:italic>NPPC<\/jats:italic>) rescues the phenotype, thus validating its potential as a therapeutic treatment for ISS. Our results show the value of looking for bidirectional effects to identify and validate drug targets.<\/jats:p>","DOI":"10.1038\/s41467-021-21843-8","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T10:05:57Z","timestamp":1618308357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Identifying therapeutic drug targets using bidirectional effect genes"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-2955","authenticated-orcid":false,"given":"Karol","family":"Estrada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Wuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teague","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyatt T.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0509-1792","authenticated-orcid":false,"given":"Yuanbin","family":"Ru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marena","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Phuc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gouri","family":"Yogalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoying Karen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan H.","family":"LeBowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lon R.","family":"Cardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"21843_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860 (2015).","journal-title":"Nat. Genet."},{"key":"21843_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-019-1879-7","volume":"577","author":"M Claussnitzer","year":"2020","unstructured":"Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179\u2013189 (2020).","journal-title":"Nature"},{"key":"21843_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41588-019-0456-1","volume":"51","author":"H Fang","year":"2019","unstructured":"Fang, H. et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat. Genet. 51, 1082\u20131091 (2019).","journal-title":"Nat. Genet."},{"key":"21843_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41588-019-0460-5","volume":"51","author":"RM Plenge","year":"2019","unstructured":"Plenge, R. M. Priority index for human genetics and drug discovery. Nat. Genet. 51, 1073\u20131075 (2019).","journal-title":"Nat. Genet."},{"key":"21843_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd4051","volume":"12","author":"RM Plenge","year":"2013","unstructured":"Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581\u2013594 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21843_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"21843_CR7","doi-asserted-by":"publisher","first-page":"E455","DOI":"10.1073\/pnas.1322563111","volume":"111","author":"O Zuk","year":"2014","unstructured":"Zuk, O. et al. Searching for missing heritability: designing rare variant association studies. Proc. Natl Acad. Sci. USA 111, E455\u2013464 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21843_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154\u2013156 (2003).","journal-title":"Nat. Genet."},{"key":"21843_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K. & Hobbs, H. H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161\u2013165 (2005).","journal-title":"Nat. Genet."},{"key":"21843_CR10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264\u20131272 (2006).","journal-title":"N. Engl. J. Med."},{"key":"21843_CR11","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.2174\/1381612824666181009100517","volume":"24","author":"VG Athyros","year":"2018","unstructured":"Athyros, V. G., Katsiki, N., Dimakopoulou, A., Patoulias, D., Alataki, S. & Doumas, M. Drugs that mimic the effect of gene mutations for the prevention or the treatment of atherosclerotic disease: from PCSK9 inhibition to ANGPTL3 inactivation. Curr. Pharm. Des. 24, 3638\u20133646 (2018).","journal-title":"Curr. Pharm. Des."},{"key":"21843_CR12","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/en.2007-0270","volume":"148","author":"R Baron","year":"2007","unstructured":"Baron, R. & Rawadi, G. Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148, 2635\u20132643 (2007).","journal-title":"Endocrinology"},{"key":"21843_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"21843_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1375\/136905203770326402","volume":"6","author":"K Silventoinen","year":"2003","unstructured":"Silventoinen, K. et al. Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res. 6, 399\u2013408 (2003).","journal-title":"Twin Res."},{"key":"21843_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4008\/jcrpe.v1i3.53","volume":"1","author":"S Pedicelli","year":"2009","unstructured":"Pedicelli, S., Peschiaroli, E., Violi, E. & Cianfarani, S. Controversies in the definition and treatment of idiopathic short stature (ISS). J. Clin. Res. Pediatr. Endocrinol. 1, 105\u2013115 (2009).","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"21843_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gim.2017.159","volume":"20","author":"NN Hauer","year":"2018","unstructured":"Hauer, N. N. et al. Clinical relevance of systematic phenotyping and exome sequencing in patients with short stature. Genet. Med. 20, 630\u2013638 (2018).","journal-title":"Genet. Med."},{"key":"21843_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","volume":"78","author":"R Shiang","year":"1994","unstructured":"Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335\u2013342 (1994).","journal-title":"Cell"},{"key":"21843_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1086\/422013","volume":"75","author":"CF Bartels","year":"2004","unstructured":"Bartels, C. F. et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am. J. Hum. Genet. 75, 27\u201334 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"21843_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ajmg.1320230309","volume":"23","author":"DO Sillence","year":"1986","unstructured":"Sillence, D. O., Barlow, K. K., Cole, W. G., Dietrich, S., Garber, A. P. & Rimoin, D. L. Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity. Am. J. Med. Genet. 23, 821\u2013832 (1986).","journal-title":"Am. J. Med. Genet."},{"key":"21843_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan, R. et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med. 381, 25\u201335 (2019).","journal-title":"N. Engl. J. Med."},{"key":"21843_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000330158","volume":"76","author":"J Dahlgren","year":"2011","unstructured":"Dahlgren, J. Growth outcomes in individuals with idiopathic short stature treated with growth hormone therapy. Horm. Res. Paediatr. 76, 42\u201345 (2011).","journal-title":"Horm. Res. Paediatr."},{"key":"21843_CR22","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","volume":"27","author":"L Yengo","year":"2018","unstructured":"Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. Hum. Mol. Genet. 27, 3641\u20133649 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"21843_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature21039","volume":"542","author":"E Marouli","year":"2017","unstructured":"Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. Nature 542, 186\u2013190 (2017).","journal-title":"Nature"},{"key":"21843_CR24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng.3097","volume":"46","author":"AR Wood","year":"2014","unstructured":"Wood, A. R. et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat. Genet. 46, 1173\u20131186 (2014).","journal-title":"Nat. Genet."},{"key":"21843_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/nature09410","volume":"467","author":"H Lango Allen","year":"2010","unstructured":"Lango Allen, H. et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467, 832\u2013838 (2010).","journal-title":"Nature"},{"key":"21843_CR26","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1093\/hmg\/ddp296","volume":"18","author":"K Estrada","year":"2009","unstructured":"Estrada, K. et al. A genome-wide association study of northwestern Europeans involves the C-type natriuretic peptide signaling pathway in the etiology of human height variation. Hum. Mol. Genet. 18, 3516\u20133524 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"21843_CR27","doi-asserted-by":"publisher","first-page":"11816","DOI":"10.1074\/jbc.272.18.11816","volume":"272","author":"AB Vaandrager","year":"1997","unstructured":"Vaandrager, A. B. et al. Endogenous type II cGMP-dependent protein kinase exists as a dimer in membranes and can Be functionally distinguished from the type I isoforms. J. Biol. Chem. 272, 11816\u201311823 (1997).","journal-title":"J. Biol. Chem."},{"key":"21843_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41588-018-0154-4","volume":"50","author":"ER Gamazon","year":"2018","unstructured":"Gamazon, E. R. et al. Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat. Genet. 50, 956\u2013967 (2018).","journal-title":"Nat. Genet."},{"key":"21843_CR29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1105136","volume":"306","author":"EP Consortium","year":"2004","unstructured":"Consortium, E. P. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 306, 636\u2013640 (2004).","journal-title":"Science"},{"key":"21843_CR30","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).","journal-title":"PLoS Genet."},{"key":"21843_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ajhg.2011.05.029","volume":"89","author":"MC Wu","year":"2011","unstructured":"Wu, M. C., Lee, S., Cai, T., Li, Y., Boehnke, M. & Lin, X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 89, 82\u201393 (2011).","journal-title":"Am. J. Hum. Genet."},{"key":"21843_CR32","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","volume":"91","author":"F Lorget","year":"2012","unstructured":"Lorget, F. et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet. 91, 1108\u20131114 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"21843_CR33","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2019","unstructured":"Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47, D886\u2013D894 (2019).","journal-title":"Nucleic Acids Res."},{"key":"21843_CR34","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/acschembio.7b00369","volume":"12","author":"JC Campbell","year":"2017","unstructured":"Campbell, J. C., Henning, P., Franz, E., Sankaran, B., Herberg, F. W. & Kim, C. Structural basis of analog specificity in PKG I and II. ACS Chem. Biol. 12, 2388\u20132398 (2017).","journal-title":"ACS Chem. Biol."},{"key":"21843_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0014-5793(95)01168-E","volume":"374","author":"D Pohler","year":"1995","unstructured":"Pohler, D. et al. Expression, purification, and characterization of the cGMP-dependent protein kinases I beta and II using the baculovirus system. FEBS Lett. 374, 419\u2013425 (1995).","journal-title":"FEBS Lett."},{"key":"21843_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00063030-200822030-00004","volume":"22","author":"GM Keating","year":"2008","unstructured":"Keating, G. M. Mecasermin. BioDrugs 22, 177\u2013188 (2008).","journal-title":"BioDrugs"},{"key":"21843_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/ng0597-54","volume":"16","author":"E Rao","year":"1997","unstructured":"Rao, E. et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat. Genet. 16, 54\u201363 (1997).","journal-title":"Nat. Genet."},{"key":"21843_CR38","doi-asserted-by":"publisher","first-page":"e66048","DOI":"10.1371\/journal.pone.0066048","volume":"8","author":"E Tassano","year":"2013","unstructured":"Tassano, E. et al. Genotype-phenotype correlation of 2q37 deletions including NPPC gene associated with skeletal malformations. PLoS ONE 8, e66048 (2013).","journal-title":"PLoS ONE"},{"key":"21843_CR39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/humu.22773","volume":"36","author":"SR Wang","year":"2015","unstructured":"Wang, S. R. et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature. Hum. Mutat. 36, 474\u2013481 (2015).","journal-title":"Hum. Mutat."},{"key":"21843_CR40","doi-asserted-by":"crossref","unstructured":"Keselman, A. C. et al. A Homozygous mutation in the highly conserved Tyr60 of the mature IGF1 peptide broadens the spectrum of IGF1 deficiency. Eur. J. Endocrinol. 181, K43\u2013K53 (2019).","DOI":"10.1530\/EJE-19-0563"},{"key":"21843_CR41","first-page":"2927","volume":"85","author":"T Ogata","year":"2000","unstructured":"Ogata, T., Kosho, T., Wakui, K., Fukushima, Y., Yoshimoto, M. & Miharu, N. Short stature homeobox-containing gene duplication on the der(X) chromosome in a female with 45,X\/46,X, der(X), gonadal dysgenesis, and tall stature. J. Clin. Endocrinol. Metab. 85, 2927\u20132930 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"21843_CR42","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/humu.20511","volume":"28","author":"R Bocciardi","year":"2007","unstructured":"Bocciardi, R. et al. Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum. Mutat. 28, 724\u2013731 (2007).","journal-title":"Hum. Mutat."},{"key":"21843_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ajmg.a.36218","volume":"164A","author":"K Miura","year":"2014","unstructured":"Miura, K. et al. Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am. J. Med. Genet. A 164A, 156\u2013163 (2014).","journal-title":"Am. J. Med. Genet. A"},{"key":"21843_CR44","doi-asserted-by":"publisher","first-page":"e42180","DOI":"10.1371\/journal.pone.0042180","volume":"7","author":"K Miura","year":"2012","unstructured":"Miura, K. et al. An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene. PLoS ONE 7, e42180 (2012).","journal-title":"PLoS ONE"},{"key":"21843_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmg.2006.03.005","volume":"50","author":"SG Kant","year":"2007","unstructured":"Kant, S. G. et al. Tall stature and duplication of the insulin-like growth factor I receptor gene. Eur. J. Med. Genet. 50, 1\u201310 (2007).","journal-title":"Eur. J. Med. Genet."},{"key":"21843_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1086\/508433","volume":"79","author":"RM Toydemir","year":"2006","unstructured":"Toydemir, R. M. et al. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am. J. Hum. Genet. 79, 935\u2013941 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"21843_CR47","doi-asserted-by":"publisher","first-page":"E1988","DOI":"10.1210\/jc.2013-2358","volume":"98","author":"SE Hannema","year":"2013","unstructured":"Hannema, S. E. et al. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. J. Clin. Endocrinol. Metab. 98, E1988\u20131998 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"21843_CR48","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2019.04.014","volume":"177","author":"X Liu","year":"2019","unstructured":"Liu, X., Li, Y. I. & Pritchard, J. K. Trans effects on gene expression can drive omnigenic inheritance. Cell 177, 1022\u20131034.e1026 (2019).","journal-title":"Cell"},{"key":"21843_CR49","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2017.05.038","volume":"169","author":"EA Boyle","year":"2017","unstructured":"Boyle, E. A., Li, Y. I. & Pritchard, J. K. An expanded view of complex traits: from polygenic to omnigenic. Cell 169, 1177\u20131186 (2017).","journal-title":"Cell"},{"key":"21843_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12869-0","volume":"10","author":"MT Oetjens","year":"2019","unstructured":"Oetjens, M. T., Kelly, M. A., Sturm, A. C., Martin, C. L. & Ledbetter, D. H. Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. Nat. Commun. 10, 4897 (2019).","journal-title":"Nat. Commun."},{"key":"21843_CR51","doi-asserted-by":"publisher","first-page":"14288","DOI":"10.1074\/jbc.C500024200","volume":"280","author":"T Tsuji","year":"2005","unstructured":"Tsuji, T. & Kunieda, T. A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn\/cn mouse. J. Biol. Chem. 280, 14288\u201314292 (2005).","journal-title":"J. Biol. Chem."},{"key":"21843_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/jpet.114.218560","volume":"353","author":"DJ Wendt","year":"2015","unstructured":"Wendt, D. J. et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J. Pharm. Exp. Ther. 353, 132\u2013149 (2015).","journal-title":"J. Pharm. Exp. Ther."},{"key":"21843_CR53","doi-asserted-by":"crossref","unstructured":"Hanley, P. C., Kanwar, H. S., Martineau, C. & Levine, M. A. Short stature is progressive in patients with heterozygous NPR2 mutations. J. Clin. Endocrinol. Metab. 105, dgaa491 (2020).","DOI":"10.1210\/clinem\/dgaa491"},{"key":"21843_CR54","doi-asserted-by":"crossref","unstructured":"Plachy L. et al. NPR2 variants are frequent among children with familiar short stature and respond well to growth hormone therapy. J. Clin. Endocrinol. Metab. 105, dgaa037 (2020).","DOI":"10.1530\/ey.17.4.11"},{"key":"21843_CR55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1515\/jpem-2016-0280","volume":"30","author":"GA Vasques","year":"2017","unstructured":"Vasques, G. A. et al. Long-term response to growth hormone therapy in a patient with short stature caused by a novel heterozygous mutation in NPR2. J. Pediatr. Endocrinol. Metab. 30, 111\u2013116 (2017).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"21843_CR56","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajhg.2020.01.003","volume":"106","author":"A Ndungu","year":"2020","unstructured":"Ndungu, A., Payne, A., Torres, J. M., van de Bunt, M. & McCarthy, M. I. A multi-tissue transcriptome analysis of human metabolites guides interpretability of associations based on multi-SNP models for gene expression. Am. J. Hum. Genet. 106, 188\u2013201 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"21843_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41588-019-0385-z","volume":"51","author":"M Wainberg","year":"2019","unstructured":"Wainberg, M. et al. Opportunities and challenges for transcriptome-wide association studies. Nat. Genet. 51, 592\u2013599 (2019).","journal-title":"Nat. Genet."},{"key":"21843_CR58","doi-asserted-by":"publisher","unstructured":"Van Hout, C. V. et al. Whole exome sequencing and characterization of coding variation in 49,960 individuals in the UK Biobank. bioRxiv https:\/\/doi.org\/10.1101\/572347 (2019).","DOI":"10.1101\/572347"},{"key":"21843_CR59","doi-asserted-by":"publisher","unstructured":"Tange O. GNU Parallel 2018 https:\/\/doi.org\/10.5281\/zenodo.1146014 (2018).","DOI":"10.5281\/zenodo.1146014"},{"key":"21843_CR60","doi-asserted-by":"publisher","unstructured":"Lin MF, et al. GLnexus: joint variant calling for large cohort sequencing. bioRxiv https:\/\/doi.org\/10.1101\/343970 (2018).","DOI":"10.1101\/343970"},{"key":"21843_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"21843_CR62","doi-asserted-by":"publisher","unstructured":"Karczewski, K. J. et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv https:\/\/doi.org\/10.1101\/531210 (2019).","DOI":"10.1101\/531210"},{"key":"21843_CR63","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ajhg.2015.09.001","volume":"97","author":"BJ Vilhjalmsson","year":"2015","unstructured":"Vilhjalmsson, B. J. et al. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. Am. J. Hum. Genet. 97, 576\u2013592 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"21843_CR64","doi-asserted-by":"publisher","first-page":"27711","DOI":"10.1074\/jbc.270.46.27711","volume":"270","author":"K Mukhopadhyay","year":"1995","unstructured":"Mukhopadhyay, K., Lefebvre, V., Zhou, G., Garofalo, S., Kimura, J. H. & de Crombrugghe, B. Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene. J. Biol. Chem. 270, 27711\u201327719 (1995).","journal-title":"J. Biol. Chem."},{"key":"21843_CR65","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/bioinformatics\/btx770","volume":"34","author":"A Derkach","year":"2018","unstructured":"Derkach, A., Zhang, H. & Chatterjee, N. Power Analysis for Genetic Association Test (PAGEANT) provides insights to challenges for rare variant association studies. Bioinformatics 34, 1506\u20131513 (2018).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21843-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:54:41Z","timestamp":1669982081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21843"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21843-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.E., A.W., C.R.B., T.S., W.T.C., L.R.C., J.H.L., S.F., M.T., H.P.N., A.R.L., D.J.W., G.K.Y., and G.Y. are employees of BioMarin Pharmaceuticals and hold common stocks. Y.R. is a former BioMarin employee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2224"}}